Skip to content

Advertisement

Open Access

Immunotoxins: experimental design

  • P Dall1 and
  • W Wels2
Breast Cancer Research20013(Suppl 1):A18

https://doi.org/10.1186/bcr342

Received: 10 May 2001

Published: 31 May 2001

Keywords

Tumor CellClinical StudyCancer ResearchAnimal ExperimentSignificant Activity

One of the major goals of tumor immunotherapy is to overcome immune escape and tumor anergy mechanisms. The identification of (relatively) tumor-specific epitopes is more important for adoptive immunotherapy strategies than their immunogenicity. In the immunocellular approach, D44v-epitope-specific T-cells were cloned introducing a fusion gene encoding the single chain Fv-fragment of CD44v-specific mAb and the zeta-chain of the TCR complex. MHC-independent retargeted cytotoxicity could be shown toward antigen-expressing tumor cells in vitro and in vivo. In a humoral approach, the fusion gene for a Her2neu-specific scFv and a bacterial toxin was expressed in E coli. After purification the fusion toxin showed significant activity in animal experiments using Her2-neu-expressing tumors. Meanwhile, the first six patients suffering from Her2-neu-expressing cancers have been treated topically so far. No significant systemic or local side effects could be detected. Four out of six patients had a local PR/CR. Further clinical studies are warranted and ongoing.

Authors’ Affiliations

(1)
Department of Obstetrics & Gynecology, Düsseldorf University Medical Center, Düsseldorf, Germany
(2)
Georg-Speyer-Haus (Chemotherapeutical Research Institute), Frankfurt, Germany

Copyright

© BioMed Central Ltd 2001

Advertisement